ES2060162T3 - Utilizacion de los anticuerpos monoclonales anti-b2 microglobulina. - Google Patents

Utilizacion de los anticuerpos monoclonales anti-b2 microglobulina.

Info

Publication number
ES2060162T3
ES2060162T3 ES90907149T ES90907149T ES2060162T3 ES 2060162 T3 ES2060162 T3 ES 2060162T3 ES 90907149 T ES90907149 T ES 90907149T ES 90907149 T ES90907149 T ES 90907149T ES 2060162 T3 ES2060162 T3 ES 2060162T3
Authority
ES
Spain
Prior art keywords
antibodies
monoclonal anti
microglobulin
microglobulin antibodies
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90907149T
Other languages
English (en)
Inventor
Jean-Claude Chermann
Pierre Corbeau
Christian Devaux
Francois Kourilsky
Francoise Rey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Application granted granted Critical
Publication of ES2060162T3 publication Critical patent/ES2060162T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A ANTICUERPOS MONOCLONICOS ANTI-B SUB 2 DE LA MICROGLOBULINA. LA INVENCION SE REFIERE TAMBIEN A LA UTILIZACION DE ESTOS ANTICUERPOS COMO MEDICAMENTO DESTINADO AL TRATAMIENTO O A LA PREVENCION DE ENFERMEDADES ASOCIADAS A UNA INFECCION VIRICA, Y A LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN ESTOS ANTICUERPOS.
ES90907149T 1989-05-03 1990-05-02 Utilizacion de los anticuerpos monoclonales anti-b2 microglobulina. Expired - Lifetime ES2060162T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8905915A FR2646607B1 (fr) 1989-05-03 1989-05-03 Anticorps monoclonaux anti-b2 microglobuline

Publications (1)

Publication Number Publication Date
ES2060162T3 true ES2060162T3 (es) 1994-11-16

Family

ID=9381409

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90907149T Expired - Lifetime ES2060162T3 (es) 1989-05-03 1990-05-02 Utilizacion de los anticuerpos monoclonales anti-b2 microglobulina.

Country Status (7)

Country Link
EP (1) EP0470989B1 (es)
AT (1) ATE108832T1 (es)
DE (1) DE69010897T2 (es)
DK (1) DK0470989T3 (es)
ES (1) ES2060162T3 (es)
FR (1) FR2646607B1 (es)
WO (1) WO1990013657A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2836146B1 (fr) 2002-02-15 2005-01-07 Urrma R & D IMMUNOGLOBULINE IgG3 MARQUEUR DE PROTECTION CONTRE LES MALADIES VIRALES INFECTIEUSES ET SES UTILISATIONS
EP3297702A4 (en) 2015-05-18 2019-01-16 The Board of Trustees of The Leland Stanford Junior University METHOD AND COMPOSITIONS FOR TREATING AGE-SATISFIED SUFFERING
WO2026024136A1 (ko) * 2024-07-26 2026-01-29 주식회사 아델 항-베타2-마이크로글로불린 항체 및 이의 용도

Also Published As

Publication number Publication date
EP0470989A1 (fr) 1992-02-19
DE69010897T2 (de) 1995-03-16
FR2646607A1 (fr) 1990-11-09
ATE108832T1 (de) 1994-08-15
EP0470989B1 (fr) 1994-07-20
WO1990013657A1 (fr) 1990-11-15
DK0470989T3 (da) 1994-11-14
FR2646607B1 (fr) 1991-08-30
DE69010897D1 (de) 1994-08-25

Similar Documents

Publication Publication Date Title
NO307968B1 (no) Pyrazolo- og pyrrolopyridiner og farmasøytisk blanding derav
EP0724651A4 (en) SYNTHETIC HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST THE VIRUS FROM HUMAN INITIATING THE IMMUNITY
EP0675904A4 (en) HUMANE NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST THE VIRUS FROM HUMAN THAT MAKES THE IMMUNE.
NO982062D0 (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
DE69133397D1 (de) Benzoylderivate
DK0841949T3 (da) Anvendelse af saccharid-konjugater
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
MA22842A1 (fr) Procede de preparation de compositions de vaccin.
TR199901710T2 (xx) IL-8 resept�r antagonistleri.
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
AP9200410A0 (en) Retroviral protease inhibitors.
DK0458699T3 (da) Anvendelse af baclofen til fremstilling af lægemidler til behandling af angina pectoris
EP0090581A3 (en) Small peptides with the specificity of foot and mouth disease viral antigens
MX9207394A (es) Esteroides de 17-espirofuran-3'-ilideno.
MX9203629A (es) Composiciones de anticuerpos monoclonales para el tratamiento profilactico o terapeutico de infecciones bacterianas debidas a estreptococos del grupo b.
GB9009106D0 (en) Processes and intermediates for synthetic antibody derivatives
DK0417003T3 (da) Anvendelse af antiprogestomimetiske forbindelser til fremme af ovulation
TR199901761T2 (xx) IL-8 resept�r antagonistleri.
FI892222A0 (fi) Peptidalkoholer med antikoagulantverkan.
ES8608884A1 (es) Un procedimiento de eliminacion del virus lav.
ES2060162T3 (es) Utilizacion de los anticuerpos monoclonales anti-b2 microglobulina.
DK190983A (da) 2,4-diamino-5-(substituerede)pyrimidiner, fremgangsmaade til deres fremstilling og mellemprodukter derfor
FI930265A0 (fi) Antikoagulantpeptider
BG101163A (bg) 8-флуоро-антрациклини, процеси за тяхното получаване и фармацевтични състави съдържащи ги
OA09197A (fr) "Peptides SDK, leur procédé de préparation ainsi que des compositions thérapeutiques en contenant".

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 470989

Country of ref document: ES